LYON, France, 25th April 2007 – Sanofi Pasteur MSD has submitted cross protection data to the European Medicines Agency (EMEA) to update the licence for the Human Papillomavirus vaccine Gardasil®. The new data come from large phase III clinical studies, including more than 17,000 womena), b), and show that Gardasil® provides benefits against pre-cancerous and potentially pre-cancerous cervical lesions caused by additional virus types not directly targeted by the vaccine. Pre-cancerous lesions (CIN[*]2/3) are the obligate precursor of cervical cancer; their prevention is the best proof for the prevention of cervical cancer. The additional virus types cause more than 10% of cervical cancer and substantial proportions of pre-cancerous and potentially pre-cancerous cervical lesions.
